BRAF and non-small cell lung carcinoma: In this study, we present a cT2bN2M0 BRAF V600E mutant NSCLC case that was initially inoperable due to N2 disease and a higher T stage than previously reported cases but achieved PR following 3 months of dabrafenib and trametinib.